MiramarLab, of Doral, Florida recalls
1 recall recorded since 2018, most recently on 18 December 2025. Status and classification are as published by the CPSC.
Recalls1
Ongoing (FDA)0
Terminated or completed0
Class I (FDA)0
Announced Consumer products
- Recall started
- 18 December 2025
- Reason
- The ointment contains lidocaine, which must be in child-resistant packaging, as required by the Poison Prevention Packaging Act. The ointment's packaging is not child-resistant, posing a risk of serious injury or death from poisoning if the contents are swallowed by young children.
- Remedy
- Consumers should immediately secure the recalled ointment jars out of the sight and reach of children and contact Plantimex to receive a free replacement lid. Once the product is secured with the replacement lid, consumers can use the product, as directed.
- Recall number
- 26157
- Mamisan Pain Relieving Topical Ointment
CPSC recall notice
A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.